Pharma Focus Europe

Lupin, in Collaboration With Mark Cuban's Cost Plus Drug Company and the COPD Foundation, Aims to Improve Medication Accessibility for COPD Patients

Thursday, September 07, 2023

Lupin Limited, a global pharmaceutical company, has formed a unique partnership with the Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) and the COPD Foundation, with the goal of improving healthcare access for COPD patients in the United States. This collaboration aims to expand the availability of Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, a generic product produced by Lupin that is therapeutically equivalent to Boehringer Ingelheim Pharmaceuticals, Inc.'s Spiriva® HandiHaler® (Tiotropium Bromide Inhalation Powder), 18 mcg/capsule.

COPD, which affects over 15 million adults in the United States and is the fourth leading cause of death in the country, poses a significant healthcare burden. This partnership marks a significant step toward addressing this burden by improving access to treatment options for COPD patients in the U.S.

Spiro Gavaris, President US Generics at Lupin, stated, "We recognize a substantial unmet need for enhanced and affordable products for patients in the United States. As a leading healthcare organization, we are dedicated to broadening access to treatment options for respiratory conditions like COPD through our respiratory portfolio and pipeline. Our collaboration with Mark Cuban Cost Plus Drug Company and the COPD Foundation underscores our commitment to offering high-quality treatment choices to patients."

Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company, shared, "We are enthusiastic about partnering with Lupin and the COPD Foundation to lower prescription drug costs for consumers. Cost Plus Drugs, Lupin, and the COPD Foundation all share a common goal of ensuring consumers receive their prescription medications at the most affordable prices possible. With Cost Plus Drugs, consumers can have confidence in obtaining a fair price and the convenience of having their medications delivered directly to their homes."

Jean Wright, M.D., CEO of the COPD Foundation, emphasized, "Accessible and affordable medications are a pathway to a healthier and more empowered life for individuals with COPD. Breathing freely should not come at the expense of financial strain. Having a generic alternative ensures that essential treatments remain accessible, allowing patients to prioritize their health."

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva